News
Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...
Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results